📊 GRCE Key Takeaways
Is GRCE a Good Investment? Thesis Analysis
Grace Therapeutics exhibits a strong balance sheet with zero debt and $18.7M in cash, but operates at a loss with negative cash flow (-$7.2M). While $100M in revenue and improving loss metrics (EPS +41.5% YoY) suggest operational progress, the company's path to profitability remains uncertain and sustainability depends on achieving operating cash flow breakeven within its ~2.6-year cash runway.
Grace Therapeutics delivers meaningful revenue (~$100M) but remains modestly loss-making with single-digit negative operating and free cash flow margins. A debt-free, highly liquid balance sheet provides multi-year runway to pursue operating leverage, yet revenue sustainability/quality and absent gross margin disclosure temper conviction. Maintain HOLD pending consistent positive operating cash flow and sustained margin expansion.
Why Buy GRCE? Key Strengths
- Fortress balance sheet: zero debt with $64.9M stockholders' equity and 14.96x current ratio provides substantial financial cushion
- Meaningful revenue base of $100M demonstrates market traction and business validation
- Improving loss metrics with 41.5% YoY EPS improvement signals operational progress toward profitability
- Debt-free balance sheet with minimal liabilities and very strong liquidity (current ratio ~15x).
- Meaningful revenue scale with EPS improving 41.5% YoY.
- Low capital intensity and manageable burn; FCF margin only -7.2%.
GRCE Investment Risks to Consider
- Operating losses of $8.1M with negative operating cash flow of $7.2M indicates company is burning cash despite revenue
- Current annual burn rate (~$7.2M) implies limited runway before cash depletion if profitability not achieved
- Pharmaceutical sector requires sustained R&D investment; uncertain timeline for achieving operating profitability and positive cash generation
- Ongoing operating and net losses with negative ROE/ROA.
- Unclear revenue quality and lack of gross margin disclosure increase volatility risk.
- Potential dilution if burn persists; typical clinical/regulatory execution risks for pharma.
Key Metrics to Watch
- Operating cash flow trend and path to breakeven - critical determinant of company viability
- Revenue growth rate and operating margin expansion toward profitability
- Cash balance depletion timeline and quarterly burn rate changes
- Operating cash flow (quarterly burn)
- Operating margin trend
GRCE Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 14.96x current ratio provides a solid financial cushion.
GRCE Profitability Ratios
GRCE vs Healthcare Sector
How Grace Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GRCE Overvalued or Undervalued?
Based on fundamental analysis, Grace Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GRCE Balance Sheet & Liquidity
GRCE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Grace Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.35 indicates the company is currently unprofitable.
GRCE Growth Metrics (YoY)
GRCE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | $981.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GRCE Capital Allocation
GRCE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Grace Therapeutics, Inc. (CIK: 0001444192)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GRCE
What is the AI rating for GRCE?
Grace Therapeutics, Inc. (GRCE) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GRCE's key strengths?
Claude: Fortress balance sheet: zero debt with $64.9M stockholders' equity and 14.96x current ratio provides substantial financial cushion. Meaningful revenue base of $100M demonstrates market traction and business validation. ChatGPT: Debt-free balance sheet with minimal liabilities and very strong liquidity (current ratio ~15x).. Meaningful revenue scale with EPS improving 41.5% YoY..
What are the risks of investing in GRCE?
Claude: Operating losses of $8.1M with negative operating cash flow of $7.2M indicates company is burning cash despite revenue. Current annual burn rate (~$7.2M) implies limited runway before cash depletion if profitability not achieved. ChatGPT: Ongoing operating and net losses with negative ROE/ROA.. Unclear revenue quality and lack of gross margin disclosure increase volatility risk..
What is GRCE's revenue and growth?
Grace Therapeutics, Inc. reported revenue of $100.0M.
Does GRCE pay dividends?
Grace Therapeutics, Inc. does not currently pay dividends.
Where can I find GRCE SEC filings?
Official SEC filings for Grace Therapeutics, Inc. (CIK: 0001444192) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GRCE's EPS?
Grace Therapeutics, Inc. has a diluted EPS of $-0.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GRCE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Grace Therapeutics, Inc. has a HOLD rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GRCE stock overvalued or undervalued?
Valuation metrics for GRCE: ROE of -10.2% (sector avg: 15%), net margin of -6.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GRCE stock in 2026?
Our dual AI analysis gives Grace Therapeutics, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GRCE's free cash flow?
Grace Therapeutics, Inc.'s operating cash flow is $-7.2M, with capital expenditures of $36.0K. FCF margin is -7.2%.
How does GRCE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6.6% (avg: 12%), ROE -10.2% (avg: 15%), current ratio 14.96 (avg: 2).